A Phase 3 Study to Evaluate the Long-Term Safety of ThermoProfen™ in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee.
This study has been terminated.
(Corporate decision)
Sponsor:
ZARS Pharma Inc.
Information provided by (Responsible Party):
ZARS Pharma Inc.
ClinicalTrials.gov Identifier:
NCT00532038
First received: September 18, 2007
Last updated: March 14, 2012
Last verified: March 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
ThermoProfen is a transdermal ketoprofen patch that is integrated with a long-lasting CHADD (Controlled Heat-Assisted Drug Delivery) unit for the treatment of chronic pain associated with osteoarthritis. This study will evaluate the safety of long-term administration of ThermoProfen™ for the pain associated with osteoarthritis of the knee in adults. The study will be conducted in patients with pain associated with osteoarthritis and who have completed a previous efficacy study of ThermoProfen.
| Condition | Intervention | Phase |
|---|---|---|
|
Osteoarthritis |
Drug: ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label, Long-Term Safety Study to Evaluate the Safety of ThermoProfen™ for the Treatment of Mild to Moderate Pain Associated With Osteoarthritis of the Knee |
Resource links provided by NLM:
MedlinePlus related topics:
Osteoarthritis
Drug Information available for:
Ketoprofen
U.S. FDA Resources
Further study details as provided by ZARS Pharma Inc.:
Primary Outcome Measures:
- To evaluate the safety of long-term administration of ThermoProfen™ [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
| Enrollment: | 179 |
| Study Start Date: | September 2007 |
| Study Completion Date: | November 2008 |
| Primary Completion Date: | November 2008 (Final data collection date for primary outcome measure) |
Intervention Details:
Detailed Description:
-
Drug: ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)
Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
The objective of the study is to evaluate the safety of long-term administration of ThermoProfen for the pain associated with osteoarthritis of the knee in adults.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient completed a previous efficacy study of ThermoProfen.
Exclusion Criteria:
- Patient has a known allergy to nonsteroidal anti-inflammatory drugs (NSAIDs) (including aspirin).
- Patient has a suspected hypersensitivity, allergy, or other contraindication to any compound present in the study medication or has a known sensitivity to adhesive components similar to those used in ThermoProfen (such as that found in adhesive bandages, e.g. Band-Aid®).
- Patient has asthma that has been induced or made worse by the use of aspirin or any other NSAID.
- Patient has a relevant history of serious gastrointestinal disease.
- Patient has a defect, injury, or dermatologic disease or condition on the skin area where the study patch will be applied that may interfere with tolerability or post-application evaluations.
- Patient has neurological or psychiatric disease sufficient to compromise data collection or integrity.
- Patient is taking warfarin, heparin, or low molecular weight heparin.
- Patient, if female, is pregnant or breastfeeding or is of childbearing potential and not practicing adequate birth control.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00532038
Locations
| United States, California | |
| Anaheim, California, United States, 92801 | |
| San Diego, California, United States, 92103 | |
| Westlake Village, California, United States, 91361 | |
| United States, Florida | |
| Clearwater, Florida, United States, 33761 | |
| Pembroke Pines, Florida, United States, 33024 | |
| United States, Illinois | |
| Springfield, Illinois, United States, 62704 | |
| United States, Indiana | |
| Evansville, Indiana, United States, 47714 | |
| United States, Kansas | |
| Overland Park, Kansas, United States, 66215 | |
| United States, Maryland | |
| Baltimore, Maryland, United States, 21239 | |
| Wheaton, Maryland, United States, 20902 | |
| United States, Missouri | |
| Kansas City, Missouri, United States, 64114 | |
| United States, New Jersey | |
| Mercerville, New Jersey, United States | |
| United States, North Carolina | |
| Raleigh, North Carolina, United States, 27612 | |
| United States, Oregon | |
| Lake Oswego, Oregon, United States, 97035 | |
| United States, Pennsylvania | |
| Duncansville, Pennsylvania, United States, 16635 | |
| Erie, Pennsylvania, United States, 16508 | |
| United States, South Carolina | |
| Anderson, South Carolina, United States, 29621 | |
| United States, Tennessee | |
| Nashville, Tennessee, United States, 37205 | |
| United States, Texas | |
| Houston, Texas, United States, 77090 | |
| San Antonio, Texas, United States, 78217 | |
Sponsors and Collaborators
ZARS Pharma Inc.
Investigators
| Study Director: | Medical Monitor | ZARS Pharma |
More Information
No publications provided
| Responsible Party: | ZARS Pharma Inc. |
| ClinicalTrials.gov Identifier: | NCT00532038 History of Changes |
| Other Study ID Numbers: | ZMK-304 |
| Study First Received: | September 18, 2007 |
| Last Updated: | March 14, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by ZARS Pharma Inc.:
|
Osteoarthritis Pain |
Additional relevant MeSH terms:
|
Osteoarthritis Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Ketoprofen Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Anti-Inflammatory Agents Therapeutic Uses Antirheumatic Agents Cyclooxygenase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Central Nervous System Agents |
ClinicalTrials.gov processed this record on June 17, 2013